We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Epigenetic Tests Being Developed for Early Lung Cancer Detection

By LabMedica International staff writers
Posted on 17 Jun 2013
RiboMed Biotechnologies, Inc. More...
(Carlsbad, CA, USA) has partnered with scientists at the Austrian Institute of Technology (AIT; Vienna, Austria) to commercialize clinically validated lung cancer DNA methylation biomarkers.

The biomarkers will allow the early detection of lung cancer, as well as the subtyping of non-small-cell lung cancer (NSCLC) into adenocarcinoma or squamous cell carcinoma, which are treated with different drugs. This detection and subtyping panel will not only allow physicians to diagnose the disease earlier but also will ensure that the patient receives the drug treatment that is specific for his/her type of cancer.

A proprietary affinity protein, MethylMagnet, to separate methylated and unmethylated DNA, and an extremely sensitive signal generation process, Abscription (abortive transcription) for detection were developed by RiboMed. The combination of these two technologies in MethylMeter assays allows RiboMed to quantitatively measure DNA methylation levels on multiple genes, even with small samples containing damaged DNA.

RiboMed’s MethylMeter Abscription-based assays provide sensitive and quantitative measurement of the extent of methylation of the regulatory regions of different genes. The assays work well in serum, saliva, sputum, urine, and formalin-fixed, paraffin-embedded (FFPE) tissue sections, making them a good choice for oncology-based clinical diagnostic, prognostic, and theranostic epigenetic tests.

AIT’s detection and subtyping panel of DNA methylation biomarkers will be coupled with additional DNA methylation biomarkers being validated by RiboMed that will predict the probability of the patient’s response to the most common drugs used to treat lung cancer.

Dr. Michelle Hanna, RiboMed CEO noted, “The discovery and development of biomarker tests for drug response is becoming an essential component of cancer treatment. By coupling AIT’s diagnostic and subtyping biomarkers with other biomarkers that predict drug response, we will provide physicians with a single test with both diagnostic and theranostic information.”

The test will be developed and offered through the Clinical Laboratory Improvement Amendments (CLIA)-certified RiboMed Clinical Services Laboratory.

Related Links:
RiboMed Biotechnologies
Austrian Institute of Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
All-in-One Molecular System
AIO M160
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.